Investor Relations

Website Notice Block

Corporate Profile

MediWound is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, we are committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries. 

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

April 25, 2024

Oral presentations include additional comparative data between EscharEx ® and SANTYL ® , and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the planned design and endpoints of the upcoming Phase III study YAVNE, Israel, April 25, 2024 (GLOBE

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

March 21, 2024

$19 million revenue in 2023; $24 million projected revenue in 2024 NexoBrid ® commercially launched in U.S., Japan, India Potential blockbuster EscharEx ® to begin Phase III in the second half of 2024 $42 million cash runway through profitability Conference c all t oday, March 21 at 8:30am Eastern